Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142948 | 0.86 | SLC6A2 (0.36) | — | |
| SCHEMBL17318781 | 0.86 | — | — | |
| SCHEMBL27189617 | 0.79 | — | — | |
| SCHEMBL2139746 | 0.77 | SLC6A2 (0.43) | — | |
| SCHEMBL2112344 | 0.75 | NAMPT (0.38) | — | |
| Hydrochloric Acid SCHEMBL1247032 | 0.75 | SLC6A2 (0.42) | — | |
| SCHEMBL18445940 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL2437534 | 0.74 | NAMPT (0.38) | — | |
| SCHEMBL24849291 | 0.73 | — | — | |
| SCHEMBL4063249 | 0.73 | CTSB (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2021-04-22 | — | — | US | disclosed |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | disclosed |
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-11-15 | — | — | US | disclosed |
| EP-3377500-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | TRPM8 1367/4885 |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | TRPM8 1367/4885 |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | TRPM8 1367/4885 |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | TRPM8 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.